Becton Dickinson & Co: management transactions · United States · SEC (Form 4)

About Becton Dickinson & Co

Becton, Dickinson and Company (BDX) is a major U.S. healthcare company listed on the NYSE in the United States. For French-, Belgian- and Swiss-based investors, BD is best viewed as a global medical technology platform with a broad industrial footprint, recurring consumables exposure, and deep relationships across hospitals, laboratories, and pharmaceutical manufacturers. The company was founded in 1897 by Maxwell Becton and Fairleigh Dickinson and is headquartered in Franklin Lakes, New Jersey. Over time, BD has evolved from a classic medical supplies manufacturer into a diversified med-tech group with strong positions in medication delivery, diagnostics, biosciences, and interventional care. BD’s business model has historically been organized around three worldwide segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical includes medication delivery systems, medication management solutions, and pharmaceutical systems. BD Life Sciences covers biosciences and diagnostic solutions, including tools used in research, clinical testing, and laboratory workflows. BD Interventional spans surgery, urology, and critical care-related products used in procedural and acute-care settings. This mix gives BD a combination of installed-base revenue, consumables, and technology-driven recurring demand that is often attractive in a defensive healthcare portfolio. Competitive positioning is anchored in scale, brand recognition, manufacturing capability, and switching costs in clinical settings. BD is widely recognized as a core supplier to hospitals and laboratories, with products that include syringes, needles, IV and infusion-related devices, specimen management tools, diagnostic platforms, and a range of interventional and surgical products. The company also has a meaningful presence in pharmaceutical delivery, where its technologies help enable drug-device combination products and biologic delivery systems. That pharma-facing exposure has become increasingly strategic as biologics, GLP-1 therapies, and specialty injectables continue to grow. Geographically, BD operates on a global basis, with significant sales and operations outside the United States, including Europe and Asia. At the same time, it maintains a large U.S. manufacturing base and has recently highlighted additional domestic investments to support supply-chain resilience and capacity expansion. This matters for investors because BD combines multinational revenue diversification with a strategically important U.S. industrial footprint. Recent developments have been important. In 2025, BD announced several product and platform milestones, including advances in wearable injector technology, pharmacy automation, and hospital interoperability solutions. The company also announced a definitive agreement to combine its Biosciences & Diagnostic Solutions business with Waters Corporation, a major portfolio step that signals a sharper focus on core medical and interventional franchises. In 2026, BD disclosed a $110 million investment to expand prefillable syringe production in the United States, supporting biologic and GLP-1 drug delivery and broader pharmaceutical reshoring. Overall, BD remains a high-quality, relatively defensive healthcare name on the NYSE, with a long operating history, strong market standing, and an active capital-allocation and portfolio-shaping agenda.